Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesiritide in Diastolic Heart Failure
NCT00309868Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2002
- Primary completion
- Dec 2003
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of nesiritide in Heart failure with preserved ejection fraction (HFpEF), sponsored by Massachusetts General Hospital. Primary endpoint: Heart filling pressures (Pulmonary Capillary Wedge Pressure) at 24 hours. Started Dec 2002; status: completed.
02
Drugs
nesiritide
03
Conditions
Heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00309868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309868.